📰 Pascal Vranckx News
Pascal Vranckx News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Pascal Vranckx. Real-time updates on events, politics, business and more.
September 16, 2023
The randomized RIGHT trial, testing 48 hours of post-PCI anticoagulation in STEMI patients, failed to document either benefit or increased risk.
May 19, 2023
NSTEMI patients with blockages are delayed getting to the cath lab and fare worse than their counterparts with STEMI.
May 18, 2022
Latest data from the MASTER DAPT trial show similar results in the subgroup of patients who underwent complex PCI as in the main trial.
May 17, 2022
Complex HBR patients had the most to gain from longer DAPT, but even here, the shorter regimen seemed to hold up.
May 19, 2021
May 18, 2021 RUC-4 (CeleCor Therapeutics), an investigational glycoprotein IIb/IIIa inhibitor (GPI) administered by subcutaneous injection, provides rapid and powerful platelet inhibition in patients with STEMI, according to findings from Cel-02, a phase IIa study. Average platelet inhibition 15 minutes after the injection increased across three doses, from 77.5% with the lowest dose to 87.5% with the middle dose and 91.7% with the highest dose ( P = 0.002 for trend), Jurriën ten Berg, MD, PhD...